Traded Sep 28 – Sep 30, 2026 · disclosed 12 to 14 days later
Want the short version?
Ask OQRO reads the filings behind this page and answers in plain words, with a link to each source.
Ask OQRO is part of OQRO Pro. Everything else on OQRO is free.
Ask OQRO reads the filings behind this page and answers in plain words, with a link to each source.
Ask OQRO is part of OQRO Pro. Everything else on OQRO is free.
Only to see which pages are hard to use, so we can fix them. Nothing is used for ads, and what you type stays hidden (Microsoft Clarity, PostHog). Privacy Policy
IBRX · NASDAQ · Biological Products, (No Diagnostic Substances)
Immunitybio (IBRX) · oqro.io/stocks/IBRX · printed today. Every figure comes from a public filing, linked on the page online. Not investment advice.
Baskets of the companies that insiders, members of Congress or funds recently reported buying, each held under a written rule.
$6.02−0.55 (−8.37%)
Close of Nov 20, 2026, vs Nov 19 · end-of-day
No open-market purchase by an insider of Immunitybio was filed in the last 90 days. The latest on record was on Jun 5, 2023.
Since 2015, Immunitybio insiders reported 15 open-market purchases and 91 sales on Forms 4 and 5, with purchases in 5 different years, most recently 2023.
In the last 90 days, 2 insiders of Immunitybio (IBRX) reported 2 open-market sales worth $1.12M in total on SEC Form 4. The largest seller by value was Cheryl Cohen, with $851K. Many insider sales follow a plan set in advance or cover taxes on stock awards; the filing says what was sold, not the reason.
Yes. Members of Congress disclosed 2 trades in Immunitybio (IBRX) in the last 12 months, each reported as a value range on a periodic transaction report. The most recent is from Rep. Lisa C. McClain (MI09).
Immunitybio's next results are expected on Feb 22, 2027, after the market closes. The date can move until the company confirms it. Insiders often trade in the weeks right after results.
From official filings only: SEC Forms 4, 5 and 144 for insiders, House and Senate periodic transaction reports for Congress, SEC Form 13F for funds, Form 8-K for company events and USAspending for federal contracts. Every record on OQRO links to its source. It is public data, not investment advice.
+198.0% (+$4.00) from Nov 20, 2025 to Nov 20, 2026 · adjusted daily closes
Adjusted close went from $2.02 on Nov 20, 2025 to $6.02 on Nov 20, 2026 (+198.0%). Disclosed in this range: 0 insider trades, 2 pre-arranged insider sales, 2 Congress trades.
Counts of filings OQRO holds, by the date each was filed or the award started. Every figure links to its official SEC, House, Senate or USAspending record.
Biological Products, (No Diagnostic Substances) company based in San Diego, Ca.
Last 12 months
+198.0%
Market value
$6.66B
S&P 500 +5.7% over the same dates. Prices adjusted for splits and dividends.
Short interest: 126M shares sold short (11.4% of shares outstanding), +2.5% vs the previous count, 10.8 days of normal trading to buy them back. FINRA, as of Oct 30, 2026. Short interest history
Revenue, fiscal 2025
$113M
+668.3% vs the year before
Net income, fiscal 2025
−$351M
A loss for the year
Shares outstanding
1.06B
As of Nov 3, 2026
Traded Sep 28 – Sep 30, 2026 · disclosed 12 to 14 days later
Sep 30, 2026$1,001–$15,000Spouse
DetailsOfficial recordSep 28, 2026$1,001–$15,000Spouse
DetailsOfficial recordInsider selling
Traded Oct 5 · filed the same day
An Immunitybio officer told the SEC about a plan to sell $7.66M of Immunitybio shares around Oct 5, 2026. The shares were not acquired as compensation. That is a tiny part of all Immunitybio shares.
Prices are daily closes from Polygon.io. Company figures come from its own SEC filings. Past moves are not a forecast. OQRO reports what was filed and never tells you what to buy or sell.
Revenue
$48.8M
+52.3% vs the same quarter a year earlier
Free cash flow, last 12 months
−$297M
This quarter −$78.3M, a year earlier −$69.6M
Net debt
—
Debt —, cash $45.1M, at Sep 30, 2026
Net income, last 12 months
−$1.11B
Operating loss: profit did not cover interest (latest fiscal year)
From the company's own quarterly and annual reports to the SEC. Free cash flow (cash from operations minus capital spending), net debt (debt minus cash) and 12-month totals are calculated by OQRO. Production rates, deliveries, approvals and guidance are in its results announcement of Nov 9, 2026.
Revenue and earnings history, 13 fiscal yearsEarnings dates and the stock's moves
Insiders of Immunitybio reported 15 open-market purchases and 91 sales since 2015; purchases in 5 different years, most recently 2023.
| Year | Bought | Sold |
|---|---|---|
| 2026 | — | $1.12M2×2 trades |
| 2023 | $289K7×7 trades | — |
| 2021 | $17K2×2 trades | $6.7M13×13 trades |
| 2020 | $45M1×1 trade | $10.1M23×23 trades |
| 2019 | — | $136K7×7 trades |
| 2018 | — | $2M30×30 trades |
| 2017 | — | $1.47M9×9 trades |
| 2016 | —1×1 trade | $494K6×6 trades |
| 2015 | $10.4M4×4 trades | $10.3M1×1 trade |
Open-market purchases (code P) and sales (code S) on Forms 4 and 5. Up to Sep 2024 from the SEC's Insider Transactions Data Sets; since Oct 2024 from each filing as it is published. A trade filed twice (an amendment) counts once. Dollar totals use the price the filer reported; lines with no price count as trades without a value.
Written by software from the filings listed below · Oct 26, 2026
4 more points, with the facts they come from, are in OQRO Pro.
Sign up freeOn the public record for Immunitybio over the 12 months to Nov 19, 2026: 14 clinical trials.
No Schedule 13D or 13G filing on IBRX over the last three years: no investor has reported crossing 5% of its stock in that time.
Source: SEC Schedules 13D and 13G, which anyone owning more than 5% of a class of stock must file. A 13D filer may seek to influence the company; a 13G filer is passive. Filings before December 2024 are free text and read from their cover page: a percent or share count that is not stated plainly is left blank. Each line links to the filing.
Written by OQRO's software from the last 12 months on record · Nov 19, 2026
3 certified in FY2026 Q3, vs 2 a year earlier. 3 positions in total, median offered wage $144K a year.
Labor condition applications for H-1B workers certified by the Department of Labor, counted by decision date (FY2026 Q3: Apr 1, 2026 to Jun 30, 2026, the latest quarter published). A certified application is a step before a visa petition, not a hire or a visa, and one application can cover several positions. Matched by employer ID number or name.
Last results
Nov 9, 2026
Within the 30 days after it, until Dec 9, 2026
Next results, expected
Feb 22, 2027
after the market closes; the date can move until the company confirms it
Purchases after results
Not enough history
From Immunitybio's own results filings (8-K Item 2.02) and its insiders' Forms 4 and 5. Many companies only let insiders trade in a period after results; OQRO does not know Immunitybio's policy and only shows the pattern in the filings. A purchase made long after results, at a company whose insiders usually buy right after them, is marked “Bought outside the usual window”.
Every number, name, date and link in the text above comes from this list; software checks that before the text is stored. This text was assembled directly from the facts, without a language model.
Insiders
Congress
Contracts, lobbying and filings
Company reports, price and press
Who holds it
Things to keep in mind
Fails to deliver: 221K shares (about $2.19M) were not delivered on time for settlement on Oct 15, 2026. SEC fails-to-deliver data.
Fails to deliver have many causes, including processing delays, and are often resolved within days.
Off-exchange trading: 52.8% of the shares traded over the latest 4 published weeks changed hands away from the exchanges (12.4% on ATS, 40.4% with other brokers), close to its 26-week average of 52.3%. Weeks of Sep 21 to Oct 16, 2026.
Fiscal year Jan 1, 2025 to Dec 31, 2025, from the annual report filed Feb 23, 2026. Read the filing
+698% on the year before ($14.2M)
−49% on the year before ($595K)
+695% on the year before ($14.2M)
Largest ATS: INTELLIGENT CROSS LLC (14.0%), MS TRAJECTORY CROSS (ATS-1) (13.0%), UBS ATS (10.8%), as a share of this stock's ATS volume over the same 4 weeks.
An ATS, often called a dark pool, is a private trading venue run by a broker where orders are not shown publicly before they trade. Other off-exchange trades are mostly retail orders filled by wholesale brokers. A high share is common and says nothing by itself about where the price goes. FINRA OTC Transparency data, published 2 weeks after each week for the largest stocks and 4 weeks for others; total volume from our daily price data.
−48% on the year before ($531K)
Every annual report has a section where the company's managers explain the year's results (Item 7, Management's discussion and analysis). In this report it runs to about 13,000 words.
ImmunityBio, Inc. is a biotechnology company focused on innovating, developing, and commercializing next-generation immunotherapies designed to activate the patient’s immune system and deliver durable protection against cancer and infectious diseases. Our approach harnesses both the adaptive and innate immune systems with the goal of restoring immune function and generating lasting immunological memory in patients. At the core of our strategy is the Cancer BioShield platform, which is designed to stimulate critical lymphocytes, including natural killer (NK) cells, cytotoxic T cells, and memory T cells via our proprietary IL-15 superagonist, ANKTIVA (nogapendekin alfa inbakicept).
And 26 more headings in the filing.
Source: SEC EDGAR, Form 10-K filed Feb 23, 2026. Revenue lines are the figures the company tags in its filing; OQRO shows a split only when its lines add up to the reported total revenue. The quote is the opening of the managers' discussion, cut at a sentence; the word count is estimated from its length. Not investment advice.
Latest annual report filed Feb 23, 2026, compared with the one filed Mar 3, 2025. Read the filing
From time to time, we may be involved in various claims and legal proceedings relating to claims arising out of our operations. We are not currently a party to any legal proceedings that, in the opinion of our management, are likely to have a material adverse effect on our business. If we are served with any such complaints, we will assess at that time any contingencies for which we may need to reserve. Regardless of the outcome, litigation can have an adverse impact on us because of defense and settlement costs, diversion of management resources, and other factors.
Source: SEC EDGAR, Form 10-K filed Feb 23, 2026. Headings are the titles the company gives each risk; OQRO compares them with the year before by their words, so a heading that was reworded a lot shows up as both new and no longer listed. Companies list the risks they face, not forecasts.
2 active phase 3 trials and 14 active phase 2 trials led by this company, mostly in long covid, sepsis, bladder cancer. The ones with the nearest registered primary completion date still ahead:
4 trials have a registered primary completion date that has already passed. That usually means the data are being analyzed, or the entry has not been updated.
Source: ClinicalTrials.gov, studies whose lead sponsor is the company or a listed subsidiary. “Primary completion” is the sponsor's own registry date for the last main data collection. It is not an approval date, it says nothing about the result, and it is often revised.
Against the S&P 500 over the year
Since Nov 18, 2025, IBRX is up 186.7% and the index fund is up 4.5%: 182 points ahead of the market. Traders call a stock that beats the index over a period a relative-strength leader.
How much IBRX moves
Beta 1.5 (1 year vs SPY)
End-of-day prices. These figures describe the past year and say nothing about what comes next. Beta: how much the stock moved, on average, for each 1% move of the S&P 500 fund over 249 trading days (1 = in step with it).